BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 2014;36:381-97. [PMID: 24715030 DOI: 10.1007/s00281-014-0423-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Mirza MK, Kim L, Kadambi PV, Chang A, Meehan SM. Membranous nephropathy transplanted in the donor kidney: observations of resolving glomerulopathy in serial allograft biopsies. Nephrology Dialysis Transplantation 2014;29:2343-7. [DOI: 10.1093/ndt/gfu333] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
2 L'Imperio V, Pieruzzi F, Sinico RA, Nebuloni M, Granata A, Smith A, Radice A, Pagni F. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain. J Nephrol 2018;31:543-50. [PMID: 29626294 DOI: 10.1007/s40620-018-0489-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
3 Hou Y, Li Y, Li W, Xiao Z, Paunovic J. Screening of Medications for Idiopathic Membranous Nephropathy Using Glomerular Whole-Genome Sequencing. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/9337088] [Reference Citation Analysis]
4 Ahmadian E, Khatibi SMH, Vahed SZ, Ardalan M. Novel treatment options in rituximab-resistant membranous nephropathy patients. International Immunopharmacology 2022;107:108635. [DOI: 10.1016/j.intimp.2022.108635] [Reference Citation Analysis]
5 Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol 2017;13:563-79. [PMID: 28669992 DOI: 10.1038/nrneph.2017.92] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 11.2] [Reference Citation Analysis]
6 Wu J, Lei G, Wang T, Dong S, Zhan X. Esculentoside A exerts anti-oxidative stress and anti-apoptotic effects in rat experimental membranous nephropathy by regulating MAPK pathway. Mol Cell Toxicol . [DOI: 10.1007/s13273-021-00194-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wu X, Liu L, Guo Y, Yang L. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults. Int J Nephrol Renovasc Dis 2018;11:241-7. [PMID: 30288080 DOI: 10.2147/IJNRD.S176665] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Dähnrich C, Saschenbrecker S, Gunnarsson I, Schlumberger W, Ronco P, Debiec H. Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. Kidney Int Rep 2020;5:182-8. [PMID: 32043032 DOI: 10.1016/j.ekir.2019.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Maifata SM, Hod R, Zakaria F, Abd Ghani F. Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management. Biomedicines 2019;7:E86. [PMID: 31683874 DOI: 10.3390/biomedicines7040086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang M, Cui Z, Zhang Y, Qu Z, Wang X, Wang F, Meng L, Cheng X, Liu G, Zhao M. Clinical and prognostic significance of glomerular C1q deposits in primary MN. Clinica Chimica Acta 2018;485:152-7. [DOI: 10.1016/j.cca.2018.06.050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
11 Li W, Zhang M, Guo Y, Liu X, Ji X, Su J, Zhang Z, Zhang F. Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy. Clinica Chimica Acta 2018;482:178-84. [DOI: 10.1016/j.cca.2018.04.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Pourlak T, Sharifi S, Vahed SZ, Ahmadian E, Cucchiarini M. The diagnostic value of immunohistochemical staining of the interstitial vascular C4d complement in membranous nephropathy. Current Issues in Pharmacy and Medical Sciences 2021;34:181-6. [DOI: 10.2478/cipms-2021-0033] [Reference Citation Analysis]
13 Sinico RA, Mezzina N, Trezzi B, Ghiggeri GM, Radice A. Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol 2016;183:157-65. [PMID: 26459770 DOI: 10.1111/cei.12729] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
14 Ronco P, Floege J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin Immunopathol 2014;36:377-9. [PMID: 25056156 DOI: 10.1007/s00281-014-0437-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hoxha E, Stahl RAK, Reinhard L, Kühnl A, Schlumberger W, Dähnrich C. A New Chemiluminescence Immunoassay for Phospholipase A2 Receptor 1 Autoantibodies Allows Early Identification of Autoantibody Recurrence in Patients With Membranous Nephropathy. Kidney Int Rep 2021;6:928-35. [PMID: 33912742 DOI: 10.1016/j.ekir.2020.12.034] [Reference Citation Analysis]
16 Gañán IN, Iturrieta-Zuazo I, Rita CG, Sayalero ÁC. Revisiting immunological and clinical aspects of membranous nephropathy. Clin Immunol 2022;:108976. [PMID: 35276323 DOI: 10.1016/j.clim.2022.108976] [Reference Citation Analysis]
17 Shi H, Hou Y, Su X, Qiao J, Wang Q, Guo X, Gao Z, Wang L. Mechanism of action of Tripterygium wilfordii for treatment of idiopathic membranous nephropathy based on network pharmacology. Ren Fail 2022;44:116-25. [PMID: 35172688 DOI: 10.1080/0886022X.2021.2024850] [Reference Citation Analysis]
18 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hou J, Zhang M, Ding Y, Wang X, Li T, Gao P, Jiang Y. Circulating CD14+CD163+CD206+ M2 Monocytes Are Increased in Patients with Early Stage of Idiopathic Membranous Nephropathy. Mediators Inflamm 2018;2018:5270657. [PMID: 30034290 DOI: 10.1155/2018/5270657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
20 Yan Z, Hu L, Xu G. Immunosuppressive Treatments for Idiopathic Membranous Nephropathy: A Pilot Study According to Histopathological Stages. Am J Med Sci 2021:S0002-9629(21)00336-0. [PMID: 34606753 DOI: 10.1016/j.amjms.2021.09.008] [Reference Citation Analysis]
21 Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, Lennon R, Brenchley PE. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 2015;26:302-13. [PMID: 25288605 DOI: 10.1681/ASN.2014050502] [Cited by in Crossref: 121] [Cited by in F6Publishing: 67] [Article Influence: 15.1] [Reference Citation Analysis]
22 Wang F, Wang TT, Liang XW, Lu JD, Xie QH, Chen RY, Xue J. PLA2R1 and HLA-DQA1 gene variations in idiopathic membranous nephropathy in South China. Ann Acad Med Singap 2021;50:33-41. [PMID: 33623956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sekula P, Li Y, Stanescu HC, Wuttke M, Ekici AB, Bockenhauer D, Walz G, Powis SH, Kielstein JT, Brenchley P, Eckardt KU, Kronenberg F, Kleta R, Köttgen A; GCKD Investigators. Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrol Dial Transplant 2017;32:325-32. [PMID: 27333618 DOI: 10.1093/ndt/gfw001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
24 Smith A, L'Imperio V, Ajello E, Ferrario F, Mosele N, Stella M, Galli M, Chinello C, Pieruzzi F, Spasovski G, Pagni F, Magni F. The putative role of MALDI-MSI in the study of Membranous Nephropathy. Biochim Biophys Acta Proteins Proteom 2017;1865:865-74. [PMID: 27890680 DOI: 10.1016/j.bbapap.2016.11.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
25 Yoshikawa M, Asaba K. Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: a meta-analysis. Sci Rep 2020;10:13119. [PMID: 32753608 DOI: 10.1038/s41598-020-70009-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Yu-Zhu X, Na-Ya H, Ya-Gui Q, Xiong-Hui C, Zhi-Jian L, Wei C, Xin W. Clinical characteristics and outcomes of idiopathic membranous nephropathy with glomerular IgM deposits. Clin Exp Med 2021. [PMID: 34698950 DOI: 10.1007/s10238-021-00768-y] [Reference Citation Analysis]
27 Wang HY, Cui Z, Xie LJ, Zhang LJ, Pei ZY, Chen FJ, Qu Z, Huang J, Zhang YM, Wang X, Wang F, Meng LQ, Cheng XY, Liu G, Zhou XJ, Zhang H, Debiec H, Ronco P, Zhao MH. HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy. Kidney Int 2018;94:974-82. [PMID: 30173899 DOI: 10.1016/j.kint.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
28 Li W, Zhao Y. Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis. Int Urol Nephrol 2019;51:1581-96. [PMID: 31140029 DOI: 10.1007/s11255-019-02147-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Silva CAD, Custódio FB, Monteiro MLGDR, Araújo SA, Araújo LS, Côrrea RRM, Reis MAD, Machado JR. Focal and Segmental Glomerulosclerosis and Membranous Nephropathy overlapping in a patient with Nephrotic Syndrome: a case report. J Bras Nefrol 2020;42:113-7. [PMID: 30806447 DOI: 10.1590/2175-8239-JBN-2018-0239] [Reference Citation Analysis]
30 Leclerc S, Benkirane K, Nadeau-Fredette AC, Elftouh N, Lafrance JP, Pichette V, Royal V, Lamarche C, Laurin LP. Qualitative and Quantitative Dosage of the Anti M-Type Phospholipase A2 Receptor Autoantibody: One-Year Experience in Quebec's Reference Center. Can J Kidney Health Dis 2021;8:20543581211052729. [PMID: 34721885 DOI: 10.1177/20543581211052729] [Reference Citation Analysis]
31 Wang YN, Ma SX, Chen YY, Chen L, Liu BL, Liu QQ, Zhao YY. Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta 2019;499:54-63. [PMID: 31476302 DOI: 10.1016/j.cca.2019.08.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
32 Pozdzik A, Beukinga I, Gu-Trantien C, Willard-Gallo K, Nortier J, Pradier O. Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy? Mediators Inflamm 2016;2016:7651024. [PMID: 27493452 DOI: 10.1155/2016/7651024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
33 Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol 2015;26:2545-58. [PMID: 25804280 DOI: 10.1681/ASN.2014070640] [Cited by in Crossref: 161] [Cited by in F6Publishing: 85] [Article Influence: 23.0] [Reference Citation Analysis]
34 Oniszczuk J, Beldi-Ferchiou A, Audureau E, Azzaoui I, Molinier-Frenkel V, Frontera V, Karras A, Moktefi A, Pillebout E, Zaidan M, El Karoui K, Delfau-Larue MH, Hénique C, Ollero M, Sahali D, Mahévas M, Audard V. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 2021;36:609-17. [PMID: 33241414 DOI: 10.1093/ndt/gfaa279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Iranzad R, Motavalli R, Ghassabi A, Pourakbari R, Etemadi J, Yousefi M. Roles of microRNAs in renal disorders related to primary podocyte dysfunction. Life Sci 2021;277:119463. [PMID: 33862110 DOI: 10.1016/j.lfs.2021.119463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Weng Q, Zhou Q, Tong J, Jin Y, Liu Y, Yu X, Pan X, Ren H, Wang W, Xie J, Chen N. New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease. Clin Proteomics 2020;17:18. [PMID: 32514258 DOI: 10.1186/s12014-020-09282-x] [Reference Citation Analysis]
37 Li SS, Tang DE, Dai Y. Advances in antigens associated with Idiopathic Membranous Nephropathy. J Formos Med Assoc 2021:S0929-6646(21)00294-1. [PMID: 34244038 DOI: 10.1016/j.jfma.2021.06.014] [Reference Citation Analysis]
38 Dauvergne M, Moktefi A, Rabant M, Vigneau C, Kofman T, Burtey S, Corpechot C, Stehlé T, Desvaux D, Rioux-Leclercq N, Rouvier P, Knebelmann B, Boffa JJ, Frouget T, Daugas E, Jablonski M, Dahan K, Brocheriou I, Remy P, Grimbert P, Lang P, Chazouilleres O, Sahali D, Audard V. Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases. Medicine (Baltimore) 2015;94:e1243. [PMID: 26222864 DOI: 10.1097/MD.0000000000001243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
39 Meyrier A, Ronco P. Allotransplantation using a diseased kidney: when a swallow makes a summer. Nephrol Dial Transplant 2014;29:2164-6. [PMID: 25378590 DOI: 10.1093/ndt/gfu336] [Reference Citation Analysis]
40 Xu J, Shen C, Lin W, Meng T, Ooi JD, Eggenhuizen PJ, Tang R, Xiao G, Jin P, Ding X, Tang Y, Peng W, Nie W, Ao X, Xiao X, Zhong Y, Zhou Q. Single-Cell Profiling Reveals Transcriptional Signatures and Cell-Cell Crosstalk in Anti-PLA2R Positive Idiopathic Membranous Nephropathy Patients. Front Immunol 2021;12:683330. [PMID: 34135910 DOI: 10.3389/fimmu.2021.683330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Lin W, Li HY, Lin S, Zhou T. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis. Drug Des Devel Ther 2019;13:2179-86. [PMID: 31308629 DOI: 10.2147/DDDT.S209211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yang Y, Liang J, Han X, Tian R, Liu X, Mao W, Xu H, Liu B, Xu P. Dual-function of triptriolide in podocytes injury: inhibiting of apoptosis and restoring of survival. Biomedicine & Pharmacotherapy 2019;109:1932-9. [DOI: 10.1016/j.biopha.2018.11.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
43 Li S, Luo Z, Meng S, Qiu X, Zheng F, Dai W, Zhang X, Sui W, Yan Q, Tang D, Dai Y. Label-free quantitative proteomic and phosphoproteomic analyses of renal biopsy tissues in membranous nephropathy. Proteomics Clin Appl 2021;:e2000069. [PMID: 34543527 DOI: 10.1002/prca.202000069] [Reference Citation Analysis]
44 Wang J, Zhu P, Cui Z, Qu Z, Zhang YM, Wang F, Wang X, Wang JW, Zhu SN, Liu G, Zhou FD, Zhao MH. Clinical Features and Outcomes in Patients With Membranous Nephropathy and Crescent Formation. Medicine (Baltimore) 2015;94:e2294. [PMID: 26683965 DOI: 10.1097/MD.0000000000002294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
45 Caza TN, Al-Rabadi LF, Beck LH Jr. How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy. Front Immunol 2021;12:800242. [PMID: 34899763 DOI: 10.3389/fimmu.2021.800242] [Reference Citation Analysis]
46 Li P, Zhong X, Zhang L, Yu Y, Niu J. Bioinformatic investigation for candidate genes and molecular mechanism in the pathogenesis of membranous nephropathy. Nephrology 2021;26:262-9. [DOI: 10.1111/nep.13833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Liu L, Chang B, Wu X, Guo Y, Pan Y, Yang L. Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy. Vasc Health Risk Manag 2018;14:103-8. [PMID: 29881283 DOI: 10.2147/VHRM.S160883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Kaya B, Paydas S, Balal M, Eren Erdogan K, Gonlusen G. Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings. Int J Clin Pract 2021;75:e13855. [PMID: 33249733 DOI: 10.1111/ijcp.13855] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Bally S, Debiec H, Ponard D, Dijoud F, Rendu J, Fauré J, Ronco P, Dumestre-Perard C. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. J Am Soc Nephrol 2016;27:3539-44. [PMID: 27153925 DOI: 10.1681/ASN.2015101155] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
50 Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 2017;91:566-74. [PMID: 28065518 DOI: 10.1016/j.kint.2016.09.048] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 14.6] [Reference Citation Analysis]
51 Zheng Q, Yang H, Liu W, Sun W, Zhao Q, Zhang X, Jin H, Sun L. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open 2019;9:e030919. [PMID: 31511292 DOI: 10.1136/bmjopen-2019-030919] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Stehlé T, Audard V, Ronco P, Debiec H. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant 2015;30:1047-50. [PMID: 25839741 DOI: 10.1093/ndt/gfv080] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
53 Lin L, Wang WM, Pan XX, Xu J, Gao CN, Zhang W, Ren H, Xie JY, Shen PY, Xu YW, Ni LY, Chen N. Biomarkers to detect membranous nephropathy in Chinese patients. Oncotarget 2016;7:67868-79. [PMID: 27634909 DOI: 10.18632/oncotarget.12014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
54 Lin C, Zheng D, Wang Y, Wang S. Clinical and pathological features of idiopathic membranous nephropathy in young people. Nephrology (Carlton) 2019;24:599-604. [PMID: 30175519 DOI: 10.1111/nep.13486] [Reference Citation Analysis]
55 Kfoury H, Mubarak M, Qannus AA, Alshareef M, Alharbi J, Alghurair H, Bin Omair A, Alshamlan N, Raddaoui L, Alkhalidi H. The histological spectrum of tubulo-reticular inclusion positive renal biopsies: a tertiary hospital experience and review of the literature. Ultrastruct Pathol 2018;42:365-8. [PMID: 30019987 DOI: 10.1080/01913123.2018.1496215] [Reference Citation Analysis]
56 Zhu H, Han Q, Zhang D, Wang Y, Gao J, Yang X, Geng W, Chen X. The clinicopathological features of patients with membranous nephropathy. Int J Nephrol Renovasc Dis 2018;11:33-40. [PMID: 29403303 DOI: 10.2147/IJNRD.S149029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]